Published in Healthcare Finance, Tax and Law Weekly, April 26th, 2006
The underwriters will be granted the right to purchase up to an additional 1,275,000 shares of common stock to cover over-allotments, if any. All of the shares are being sold by Amylin Pharmaceuticals.
Morgan Stanley & Co. Incorporated is acting as the sole bookrunning and joint lead manager for the offering. Goldman, Sachs & Co. is acting as a non-bookrunning joint-lead manager of the offering....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.